Services
Basic Oncology Research
Integrated Carcinogenic Factor Analysis
Exposome Biomonitoring & Environmental Carcinogen Detection
DNA Adductomics & Genotoxic Exposure Assessment
Radiation & UV induced Damage Detection
Mutational Signature Profiling & Exposure Attribution
Polygenic Risk Score-Environment Interaction Analysis
Cancer Predisposition & Susceptibility Gene Panel Analysis
Environmental Stress-Epigenetic Alteration Profiling
Exposure-Responsive Transcriptome Analysis
Virus associated Carcinogenesis Mechanism Analysis
Organoid & Cell based Carcinogen Mechanistic Validation
Antigen Processing & Immune Checkpoint-Exposure Impact Analysis
Integrated Carcinogenic Factor Evaluation & IARC Classification Mapping
Multi-Omics Data Integration for Gene-Environment Interaction Analysis
Computational Modeling & Machine Learning Risk Stratification Analysis
Customized Gene-Environment Interaction Dashboard & Reporting Analysis
Tumor Cell Proliferation Analysis
Integrated Genome Instability & Mutation Analysis
Gene Mutation Profiling & Driver Mutation Detection
Chromosomal Instability & Copy Number Variation Analysis
Replication Stress & DNA Damage Quantification
DNA Damage Response Defect Analysis
Telomere Dysfunction & ALT Mechanism Profiling
Mutational Signature Attribution Analysis
Phenotypic Consequence Mapping
Comprehensive Oncogene & Tumor Suppressor Profiling
Oncogene Profiling
Tumor Suppressor Gene Profiling
MicroRNA-Oncogene/Tumor Suppressor Interaction Analysis
Integrated Oncogene-Tumor Suppressor Signature & Risk Score Modeling
Oncogene-Tumor Suppressor Interaction Network Visualization Analysis
Comprehensive Cancer Epigenetic Mapping
DNA Methylation Mapping & Profiling
Histone Modification & Chromatin Remodeling
Chromatin Accessibility Mapping
Epitranscriptomics & Multi-Omics Integration Analysis
Integrated Non-coding RNA Characterization
Comprehensive miRNA Profiling & Functional Analysis
Comprehensive lncRNA Profiling & Functional Analysis
Comprehensive Circulating RNA/miRNA Profiling & Functional Analysis
ncRNA-Protein/RNP Interaction Analysis
ncRNA-Centric Multi-Omics Integration Analysis & Reporting
Integrated Cell Cycle Dysregulation Analysis
Genomic Alteration Assessment
Cell Cycle Functional Validation
Advanced & Integrative Cell Cycle Services
Integrated Cancer Stem Cell Research
Cancer Stem Cell Biomarker & Subtyping Research
Cancer Stem Cell Immune Microenvironment & Niche Characterization
Cancer Stem Cell Functional
In Vitro
&
In Vivo
Analysis
Cancer Stem Cell Immunotherapy & Engineered Cell Research
Cancer Stem Cell Drug Delivery Development
Cancer Stem Cell Combination Therapy & Translational Research
Cancer Stem Cell Bioinformatics & Multi-Omics Analysis
Cancer Stem Cell Diagnostic & Predictive Testing
Replicative Immortality & Telomerase Activation Analysis
Integrated Tumor Angiogenesis & Vascular Evaluation
Endothelial Tube Formation & Sprouting Analysis
Endothelial Cell Migration & Invasion Analysis
Microfluidic Vascular Modeling & Extravasation Simulation
3D Tumor Vascular Network Bioprinting & Perfusion Evaluation
In Vivo
Vascular Network Formation & Matrigel Plug Assay
Vascular Morphology & Radiomic Biomarker Analysis
Vascular Perfusion & Permeability Evaluation
Vascular Gene & Protein Expression Profiling
Angiogenesis Regulatory Network & Pathway Integration Analysis
Angiogenesis-Tumor Microenvironment Interaction Modeling
Vascular Evaluation Profiling & Reporting
Cancer Signaling Pathway Mapping & Validation
Cancer Metabolic Reprogramming Analysis
Tumor Energy Metabolism Analysis
Tumor Metabolism Characterization
Functional Genetic Screening
Tumor Model Construction
In Vivo
Tumor Metabolism Analysis
Small Molecule Drug Discovery
End-to-End Small Molecule Immunotherapy Development
Integrated Small Molecule Target Discovery
Integrated Small Molecule Hit Discovery
Integrated Small Molecule Lead Optimization
Integrated Small Molecule
In Vitro
Immune Evaluation
Integrated Small Molecule
In Vivo
Pharmacology & Biomarker Evaluation
Integrated Small Molecule DMPK & Toxicology Evaluation
Integrated CMC Development & Support
Biologic Therapeutics Development
Antibody & Protein Discovery
Target Discovery & Validation
Antibody Discovery
Antibody Engineering
Antibody & Protein Production
Preclinical Testing
Structure & Biochemical Characterization
Preclinical Testing Bioassays & Immunoassays
Efficacy Models
Antibody & Protein Pharmacology
Antibody & Protein Toxicology
In Vitro
ADME
Permeability Analysis
Aqueous Solubility Analysis
Cell based Lysosomotropism Assay
Cell based Mitochondrial Toxicity Analysis
Cell based Phospholipidosis Analysis
Cell based Phototoxicity Analysis
HPLC-MS/MS based Glucuronide Conjugate Detection
HPLC-MS/MS based Half-life Assessment
HPLC-MS/MS based Linearity Assessment
LC-MS/MS based Quantitative Bioanalysis
Partition Coefficient Determination
Plasma Stability Determination
Compound Recovery Determination
Brain Tissue Binding Evaluation
Dosing Solution Analysis
Cellular Stress Assessment
Blood Partitioning Analysis
Salmonella Strains based Ames Fluctuation Test
HepG2 based Cytotoxicity Assay
Induction Measurement
Inhibition Assessment
Ion Channel Assay
In Vitro
CYP2C9 Intrinsic Clearance Measurement
In Vitro
CYP2C19 Intrinsic Clearance Measurement
In Vitro
CYP2D6 Intrinsic Clearance Measurement
In Vitro
CYP3A4 Intrinsic Clearance Measurement
In Vitro
CYP2C8 Intrinsic Clearance Measurement
In Vitro
CYP2B6 Intrinsic Clearance Measurement
In Vitro
CYP1A2 Intrinsic Clearance Measurement
UGT Phenotyping Assay
MATE Substrate Assessment
Caco-2 based MRP2 Substrate Assessment
Caco-2 based P-gp Substrate Assessment
MDCKII based P-gp Substrate Assessment
Cell based ASBT Substrate Assessment
Caco-2 based BCRP Substrate Assessment
Caco-2 based Efflux Transporter Substrate Assessment
BJ Cell based Cytotoxicity Safety Screening
HEK293 based Cytotoxicity Safety Screening
H4-II-E-C3 based Cytotoxicity Safety Screening
HepG2 based Cytotoxicity Safety Screening
HUVEC based Cytotoxicity Safety Screening
Jurkat Cell based Cytotoxicity Safety Screening
MRC-5 based Cytotoxicity Safety Screening
Neuro-2a based Cytotoxicity Safety Screening
NIH/3T3 based Cytotoxicity Safety Screening
NRK-52E based Cytotoxicity Safety Screening
SH-SY5Y based Cytotoxicity Safety Screening
SK-N-SH based Cytotoxicity Safety Screening
HK-2 based Cytotoxicity Safety Screening
Cell Viability Measurement
AHR Nuclear Receptor Assay
CAR3 Nuclear Receptor Assay
PXR Nuclear Receptor Assay
CDMO
Cell Line Development
Cell Banking
Process & Formulation Development
Analytical & Bioassay Quality Control
Pharmaceutical Stability Analysis
Lot Release Testing
cGMP Manufacturing
IND Regulatory
Therapeutic Modality Portfolio
Modality
Antibody-Drug Conjugate Therapy Development
Bispecific Antibody Therapy Development
Next™ CAR-T Therapy Development
FucoID Technology Platform
Binding & Interaction Assay
Function Assays
FH-Bind™ Platform
NewFlexi™ ISErs Technology Platform
Mi-LOAD™ Micelle Technology Platform
SE-Enzym™ TME Targeting Chemotherapy Technology Platform
VisiMonitor™
18
F-FAraG PET Tracer
Hyperimmune Mammalian Milk based Polyclonal IgG Technology
MicroRNA Gene Silencing based CAR T-Cell Development Platform
Intratumoral Treg Assay
Predictive Biomarker Analysis
High-Throughput Antibody Production Platform
High-Throughput Neoantigen/HLA Complex Analysis
T Cell Gene Signature Technology & Analysis
CBpHLA™ Cancer Target Identification & TCR Engineering
Next™ Bifunctional mAb Pair Development
Next™ Nano based NK Engager Development
Next™ Immunocytokine Engineering Development
Next™ PEG modified Cytokine Development
High-Content Multiplexed Cell & Bead based Detection
Synthetic Gene Circuit
Cancer Cell Self-Destruction Engineering
Cancer Cell Engineering Strategies
Self-Destruction Assays
Ex Vivo
Immune Reactivity Assessment
Toxicity Assessment
Circuit Performance Assessment
Cytokine Immunotherapy Development
Advanced Cytokine Engineering
Therapeutic Cytokine Development
Cytokine Engineering
Antibody-directed Enzyme Prodrug Therapy
Enzyme Selection & Optimization
Pre-enzyme Drug Design
Pre-enzyme Modification
Antibody & Pre-enzyme Drug Coupling
In Vitro
Experiment
Animal Modeling
Safety & Toxicity Assessment
Pharmacokinetic & Pharmacodynamic Analysis
Innovative Sono-Immunotherapy Solutions
Targeted Sonosensitizer Optimization
Sonosensitizer & Nanoparticle Conjugation
In Vitro
Antitumor Effect Study
In Vivo
Antitumor Effect Study
Regulatory T Cell Therapy Development
Treg Subpopulation Expression Profiling
Treg Functional Profiling
In Vitro
Treg Suppression Assay
Treg Migration Assay
Treg Effect Assessment
Autologous Fibroblast Therapy Development
APC & Immunomodulatory Therapy Development
Next-Generation APC based Cancer Immunotherapy Development
Immunomodulatory & Cytokine based Therapy Development
Specialized Therapeutic Modality Development
Venom Peptide Development
Immuno-Toxin Development
Immunogenic Cell Death Inducer Development
Pattern Recognition Receptor Agonist Development
Multiplexed Endogenous Gene Activation based Immunotherapy Development
Neoantigen based Cancer Immunotherapy Development
Neoepitope Identification
Neoantigen Immunogenicity Assessment
Neoantigen Specific TCR Functional Analysis
Neoepitope Specific T Cell Isolation
Advanced Gene Circuit & ATMP Development
Custom Gene Circuit Development
Cell Culture for ATMP Development
Advanced Nanomedicine & Conjugate Development
Nanomedicine Development
Targeted Immuno-Stimulatory Conjugate Development
MOA Solutions
DNA targeting Therapeutic Development
Computer-Aided New DNA targeting Therapeutic Screening
Structure based DNA targeting Therapeutic Development
DNA Damage Response targeting Therapeutic Development
Exploring Synthetic Lethality for DNA targeting Therapeutic Development
DNA Repair Pathway targeting Therapeutic Development
DNA Epigenetic Modification targeting Therapeutic Development
DNA Hypermethylation targeting Therapeutic Development
Targeting Ferroptosis Solutions
Ferroptosis Inducer/Inhibitor Development
Ferroptosis Signaling Pathway related Target Screening
Ferroptosis Index Detection
Tumor Cell Ferroptosis
Ferroptosis based Cancer Therapy Discovery
Metabolism Inhibitor Development
Nucleotide Synthesis Inhibitor Development
Glucose Metabolism Inhibitor Development
Glutamine Metabolism Inhibitor Development
Fatty Acid Synthesis Inhibitor Development
IDO Inhibitor Development
Targeting Tumor Microenvironment
Inducing Immunogenic Tumor Cell Death
Targeting Tumor Microenvironment
Co-Development Program by Targets
Next-IO™ T Cell related Therapeutics
Next-IO™ Anti-FGL1 Monoclonal Antibody Program
Next-IO™ Anti-FGL2 Monoclonal Antibody Program
Next-IO™ Anti-Siglec-15 Monoclonal Antibody Program
Next-IO™ Anti-TIM3 Monoclonal Antibody Program
Next-IO™ Anti-4-1BB Monoclonal Antibody Program
Next-IO™ Anti-CD19 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD27 Monoclonal Antibody Program
Next-IO™ Anti-CD40L Monoclonal Antibody Program
Next-IO™ Anti-GITR Monoclonal Antibody Program
Next-IO™ Anti-ICOS Monoclonal Antibody Program
Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program
Next-IO™ Anti-HVEM/TNFRSF14 Monoclonal Antibody Program
Next-IO™ Anti-VISTA Monoclonal Antibody Program
Next-IO™ Anti-PD1 × TIM3 Bispecific Antibody Program
Next-IO™ Anti-TIGIT Monoclonal Antibody Program
Next-IO™ Anti-BTLA Monoclonal Antibody Program
Next-IO™ Anti-CD160 Monoclonal Antibody Program
Next-IO™ Anti-CTLA-4 × CD40 Combination Antibody Program
Next-IO™ Anti-PD-L1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD20 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD96 Therapeutic Monoclonal Antibody Program
Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program
Next-IO™ APC related Therapeutics
Next-IO™ Anti-B7-H4 × CD3 Bispecific Antibody Program
Next-IO™ Anti-B7-H3 × CD3 Bispecific Antibody Program
Next-IO™ Anti-4-1BBL Therapeutic Fusion Protein Program
Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD70 Therapeutic Fusion Protein Program
Next-IO™ Anti-CD70 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-ICOSL Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-HHLA2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-9 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD112 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD155 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-OX40L Therapeutic Fusion Protein Program
Next-IO™ Anti-GITRL Therapeutic Fusion Protein Program
Next-IO™ NK Cell related Therapeutics
Next-IO™ Fusion Proteins of NKG2D Program
Next-IO™ Anti-sMIC Monoclonal Antibody Program
Next-IO™ Anti-CD48 Monoclonal Antibody Program
Next-IO™ Anti-2B4 Monoclonal Antibody Program
Next-IO™ Anti-HLA-G Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL1-3 Monoclonal Antibody Program
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program
Next-IO™ Anti-PVR Monoclonal Antibody Program
Next-IO™ Anti-CD96 Monoclonal Antibody Program
Next-IO™ Anti-CD16 IgG Program
Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
Next-IO™ Anti-KLRG1 Monoclonal Antibody Program
Next-IO™ Anti-Cadherin Monoclonal Antibody Program
Next-IO™ Anti-LLT1 Monoclonal Antibody Program
Next-IO™ Anti-NKRP1A Monoclonal Antibody Program
Next-IO™ Targeting Sialic Acid Program
Next-IO™ Anti-Nectin-2 Monoclonal Antibody Program
Next-IO™ Tumor Associated Antigens
Next-IO™ Anti-CD73 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPVI Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Phosphatidylserine Monoclonal Antibody Program
Next-IO™ Anti-CD47 Therapeutic Monoclonal Antibody Program
Next-IO™ CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-Ang2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD123 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × PD-L1 Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × MSLN Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ TGF-β × PD-L1 Bi-Functional Therapeutic Fusion Protein Program
Next-IO™ Anti-GPC3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPA33 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPC3 Therapeutic CAR-T Cell Program
Next-IO™ Anti-GPC3 Therapeutic CAR-NK Cell Program
Next-IO™ Anti-MUC16 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CDH3 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SSTR2 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-MSLN Therapeutic Fusion Protein Program
Next-IO™ Anti-MSLN × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × CD20 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific DART Program
Next-IO™ Anti-CD24 Monoclonal Antibody Program
Next-IO™ PD-L1 × TIM-3 Therapeutic Bispecific Antibody Program
Next-IO™ PD-1 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ PSCA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ 4-1BB × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 Therapeutic Vaccine Program
Next-IO™ Anti-LAG-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-YTHDF1 Therapeutic Monoclonal Antibody Program
Next-IO™ c-MET × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ CD22 × CD19 Therapeutic CAR-T Program
Next-IO™ CD22 Therapeutic CAR-T Program
Next-IO™ CTLA-4 × OX40 Therapeutic Bispecific Antibody Program
Next-IO™ GITR × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ HER2 × HER3 Therapeutic Bispecific Antibody Program
Next-IO™ HER3 Therapeutic Monoclonal Antibody Program
Next-IO™ LAG-3 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ LAG-3 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ LGR5 Therapeutic Monoclonal Antibody Program
Next-IO™ MHC I:LILRB2 Axis Therapeutic Monoclonal Antibody Program
Next-IO™ PAUF Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-A3AR Therapeutic Monoclonal Antibody Program
Next-IO™ Macrophage related Therapeutics
Next-IO™ TAM related Therapeutics
Next-IO™ Anti-CD11b Therapeutic Monoclonal Antibody Program
Next-IO™ IL-4R Therapeutic Fusion Protein Program
Next-IO™ COX2 Therapeutic Monoclonal Antibody Program
Next-IO™ Ang-2 & VEGF Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SIRPα Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-iNOS Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-SOCS3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD163 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-SR-B1 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-TGM2 Therapeutic Monoclonal Antibody Program
Next-IO™ VEGF × DLL4 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-DLL4 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-DLL3 Therapeutic Monoclonal Antibody Program
Next-IO™ SIRPα-Fc Fusion Protein Program
Next-IO™ Anti-Siglec-10 Therapeutic Monoclonal Antibody Program
Next-IO™ B Cell related Therapeutics
Next-IO™ Chemokines & Chemokine Receptors-Related Therapeutics
Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic Antibody Program
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Alzheimer's Disease Therapeutics
Next-IO™ Anti-Amyloid-β Monoclonal Antibody Program
Translational Support
Tumor Profiling
Tumor Profiling Technology
Tumor Profiling in Diverse Cancer
Tumor Profiling Applications
Metastatic Tumor Microbiome Analysis
Intratumoral Microbiota Analysis
Gut Microbiota based Diagnostic Platform
Gut Microbial Biomarker Discovery
Gut Microbiota Analysis & Characterization
Predictive Computational Modeling
Gut Microbiota & Host Interaction Study
Gut Microbiome Model Development & Validation
Cancer Microbiome Profiling
Cancer Metabolomics Analysis
Gut Microbiome Signature Identification
BIGaxis™ Brain-Immune-Gut based Integrative Research
BIGaxis™ Brain-Immune-Gut Interaction Study
BIGaxis™ Gut Microbiota in Therapeutic & Diagnostic Research
Gut Microbiota & Neuro Disease
Cancer Resistance Integrated Solutions
Cancer Resistance Mechanism Analysis
Overcoming Cancer Resistance
Graft-Versus-Host Disease Research
GVHD Diagnosis Research
GVHD Biomarker Prediction
GVHD Therapy Discovery
Immunophenotyping
Cell Status Characterization
Cell Population Characterization
Disease Recognition
Nanomedicine
Cardiotoxicity Analysis & Prevention
Cardiotoxicity Analysis
Cardiotoxic Animal Modeling
Cardiotoxicity Prevention & Intervention
Human Oncology Imaging
In Vivo
Tumor Lineage Tracing
Tumor Contrast Imaging Solutions
Products
Oncology Cell Lines
Stable Cell Lines
Cancer Cell Lines
Reporter Cell Lines
Luciferase Cell Lines
EGFP Cell Lines
Dual Labeled Cell Lines
Gene Editing Cell Lines
KO Cell Lines
Knockin Cell Lines
Knockdown Cell Lines
Primary Cells
Stem Cells
Drug Resistant Cells
Single Clone Cells/Cell Pools
OncoImmune Cells
Oncology Kits
Consumables
Tumor Marker Kits
Oncology Assay Tools
Metabolomics Analysis Tools
Animal Models
Synthetic Gene Circuit Cells
Cell Transport Capsule Kits
ADME
Absorption
Distribution
Metabolism
Excretion
Collaborations
Company
About Us
Contact Us
Careers
Online Inquiry
Webinars
Events
Service
Product
Search
Home
Products
Oncology Cell Lines
PharmaOnco™ KP-4 Cancer Cell Line
Inquiry
Datasheet
CAT#:
ITS-0523-LX89
Product Type:
Cancer Cell Line
Organism:
Human
Overview
Applications
in vitro
and
in vivo
assay
Organism
Human
Tissue
Pancreas
Disease
pancreatic tumor
Morphology
Epithelial-like
Biosafety Level
BSL-2
Split Ratio
1:3 to 1:6
Medium Renewal
2 to 3 times per week
Specification
Oncology Cell Line
KP-4
Quantity
>1 million cell/vial
Unit Size
2 vials
Culture Properties
Adherent
Cell Viability
>80%
Sterility Testing
Sterility testing in accordance with USP and EP regulations.
Identity Testing
STR identification
Mycoplasma Testing
Negative
Shipping
Dry Ice
Storage
Frozen cells should be stored in a liquid nitrogen tank.
Warnings
Avoid multiple freeze/thaw cycles
Related Products
PharmaOnco™ SIRP alpha / HEK293 Recombinant Cell Line (Human)
(CAT#: IOC-02P097)
Human TLR8 Recombinant Cell Line, HEK293
(CAT#: IOC-LX140)
PharmaOnco™ HEK293T-Tg(Human BB2 Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM50)
PharmaOnco™ HEK293T-Tg(Human H2 Receptor) Division-Arrested Cell, Single Clone
(CAT#: ITS-0624-HMM594)
PharmaOnco™ CD137/NF-kappa B Reporter - HEK293 Recombinant Cell Line (Human)
(CAT#: IOC-02P048)
PharmaOnco™ Human A2058 Cancer Cell Line
(CAT#: IOC-ZP260)
PharmaOnco™ HEK293T-Tg(Human CCR2 Receptor) Division-Arrested Cell, Single Clone
(CAT#: ITS-0624-HMM531)
Human CD155 Recombinant Cell Line, HEK293
(CAT#: IOC-LX076)
For Research Use Only | Not For Clinical Use
Online Inquiry
Send